



ImmuSmol SAS 229 Cours de l'Argonne / 33000 Bordeaux / France

LDN Labor Diagnostika Nord GmbH & Co.KG Am Eichenhain 1 / 48531 Nordhorn / Germany

Instructions for use 3-CAT ELISA Fast Track



BA E-6600



IVD CE

Table of contents

1.	Introduction	4
1.1	Intended use and principle of the test	4
1.2	Clinical application	4
2.	Procedural cautions, guidelines, warnings and limitations	4
2.1	Procedural cautions, guidelines and warnings	4
2.2	Limitations	5
2.2.1	Interfering substances and proper handling of specimens	5
2.2.2	Drug and food interferences	5
2.2.3	High-Dose-Hook effect	5
3.	Storage and stability	5
4.	Materials	5
4.1	Contents of the kit	5
4.2	Calibration and Controls	8
4.3	Additional materials required but not provided in the kit	8
4.4	Additional equipment required but not provided in the kit	8
5.	Sample collection, handling and storage	8
6.	Test procedure	8
6.1	Preparation of reagents and further notes	9
6.2	Sample preparation, extraction and acylation	9
6.3	Adrenaline ELISA	10
6.4	Noradrenaline ELISA	10
6.5	Dopamine ELISA	11
7.	Calculation of results	11
7.1	Expected reference value	11
7.2	Typical standard curve	12
8.	Control samples	12
9.	Assay characteristics	12
9.1	Performance data	12
10.	References/Literature	14
11.	Changes	15

Related Products:

- Adrenaline ELISA Fast Track
- Noradrenaline ELISA Fast Track
- Dopamine ELISA Fast Track
- 2-CAT ELISA Fast Track

1. Introduction

1.1 Intended use and principle of the test

Enzyme Immunoassay for the quantitative determination of adrenaline (epinephrine), noradrenaline (norepinephrine) and dopamine in plasma and urine.

Adrenaline (epinephrine), noradrenaline (norepinephrine) and dopamine are extracted by using a cis-diol-specific affinity gel, acylated and then converted enzymatically.

The subsequent competitive ELISA uses the microtiter plate format. The antigen is bound to the solid phase of the microtiter plate. The acylated standards, controls and samples compete with the solid phase bound analytes for a fixed number of antibody binding sites. After the system is in equilibrium, free antigen and free antigen-antibody complexes are removed by washing. The antibody bound to the solid phase is detected by an anti-rabbit IgG-peroxidase conjugate using TMB as a substrate resulting in a colour reaction. The reaction is monitored at a wavelength of 450 nm.

Quantification of unknown samples is achieved by comparing their absorbance with a reference curve prepared with known standard concentrations. Manual processing of the ELISA is recommended. The use of automatic laboratory equipment is the responsibility of the user. This in-vitro diagnostic is for professional use only.

1.2 Clinical application

In humans the catecholamines adrenaline (epinephrine), noradrenaline (norepinephrine) and dopamine are neurotransmitters of the sympathetic nervous system and are involved in many physiological processes. The sympathetic nervous system sets the body to a heightened state of alert, also called as the body's fight-or-flight response.

In the human body the catecholamines and their metabolites indicate the adaptation of the body to acute and chronic stress.

Next to the metanephrine/normetanephrine the catecholamines are important for the diagnosis and the follow-up of tumors of the sympathoadrenal system like the pheochromocytoma. The quantitative determination of catecholamines in urine is preferred for the diagnosis of these tumors, whereas the determination of catecholamines in plasma is medically sensible for the localization of the tumor and for function testing. Values above the cut-off can provide an indication for neuroendocrine tumors.

However, in literature various diseases like hypertension, cardiovascular diseases, schizophrenia and manic depression are described with abnormal low or high levels of catecholamines.

Therapeutic consequences should never be based on laboratory results alone, even if these results are assessed in accordance with the quality criteria of the method. Any laboratory result is only a part of the total clinical picture of the patient.

Only in cases where the laboratory results are in an acceptable agreement with the overall clinical picture of the patient, it can be used for therapeutic consequences.

2. Procedural cautions, guidelines, warnings and limitations

2.1 Procedural cautions, guidelines and warnings

- (1) This kit is intended for professional use only. Users should have a thorough understanding of this protocol for the successful use of this kit. Only the test instruction provided with the kit is valid and must be used to run the assay. Reliable performance will only be attained by strict and careful adherence to the instructions provided.
- (2) This assay was validated for a certain type of sample as indicated in Intended Use (please refer to Chapter 1). Any off-label use of this kit is in the responsibility of the user and the manufacturer cannot be held liable.
- (3) The principles of Good Laboratory Practice (GLP) must be followed.
- (4) In order to reduce exposure to potentially harmful substances, wear lab coats, disposable protective gloves and protective glasses where necessary.
- (5) If serious incidents should occur in connection with this product, they should be reported to the manufacturer and the competent national authorities.
- (6) All kit reagents and specimens should be brought to room temperature and mixed gently but thoroughly before use. For dilution or reconstitution purposes, use deionized, distilled, or ultra-pure water. Avoid repeated freezing and thawing of reagents and specimens.
- (7) The microplate contains snap-off strips. Unused wells must be stored at 2 8 °C in the sealed foil pouch with desiccant and used in the frame provided. Microtiter strips which are removed from the frame for usage should be marked accordingly to avoid any mix-up.
- (8) Standards, Controls and specimen samples should be assayed in duplicate.
- (9) Once the test has been started, all steps should be completed without interruption. Make sure that the required reagents, materials, and devices are prepared for use at the appropriate time.
- (10) Incubation times do influence the results. All wells should be handled in the same order and time intervals.
- (11) To avoid cross-contamination of reagents, use new disposable pipette tips for dispensing each reagent, sample, standard and control.
- (12) A standard curve must be established for each run.

Version: 20.0

- (13) The controls should be included in each run and fall within established confidence limits. The confidence limits are listed in the QC-Report provided with the kit.
- (14) Do not mix kit components with different lot numbers within a test and do not use reagents beyond expiry date as shown on the kit labels.
- (15) For information about hazardous substances included in the kit please refer to Safety Data Sheet (SDS). The Safety Data Sheet for this product is made available directly on the website of the manufacturer or upon request.
- (16) Kit reagents must be regarded as hazardous waste and disposed of according to national regulations.
- (17) The expected reference values reported in this test instruction are only indicative. It is recommended that each laboratory establishes its own reference intervals.
- (18) In case of any severe damage to the test kit or components, the manufacturer has to be informed in writing, at the latest, one week after receiving the kit. Severely damaged single components must not be used for a test run. They must be stored properly until the manufacturer decides what to do with them. If it is decided that they are no longer suitable for measurements, they must be disposed of in accordance with national regulations.
- (19) The results obtained with this test kit should not be taken as the sole reason for any therapeutic consequence but must be correlated to other diagnostic tests and clinical observations.

2.2 Limitations

Any inappropriate handling of samples or modification of this test might influence the results.

2.2.1 Interfering substances and proper handling of specimens

Plasma

Samples containing precipitates or fibrin strands or which are hemolytic or lipemic might cause inaccurate results. Hemolytic samples (up to 4 mg/ml hemoglobin), icteric samples (up to 50 mg/dl bilirubin) and lipemic samples (up to 800 mg/dl triglycerides) have no influence on the assay results.

If the concentrations cannot be estimated and there are doubts as to whether the above limit values for hemolytic, icteric or lipemic samples are complied with, the samples should not be used in the assay.

24-hour urine

Please note the sample collection! If the percentage of the final concentration of acid is too high, this will lead to incorrect results for the urine samples.

2.2.2 Drug and food interferences

Medications such as antihypertensive drugs, antidepressants, sympathomimetics, antipsychotics and L-DOPA can affect the concentrations of catecholamines. Discontinuation of medication before the collection period must be discussed with the attending physician.

Caffeinated beverages, alcohol, nicotine, mood-enhancing drugs and catecholamine-rich foods (such as bananas, cheese, nuts, chocolate, tomatoes or beans) can also affect the concentrations of catecholamines and should be avoided from 3 days before and during the collection period (urine). Care should also be taken to avoid stress and physical strain shortly before and during the collection period.

2.2.3 High-Dose-Hook effect

No hook effect was observed in this test.

3. Storage and stability

Store kit and reagents at 2 - 8 °C until expiration date. Do not use kit and components beyond the expiry date indicated on the kit labels. Once opened, the reagents are stable for 2 months when stored at 2 - 8 °C. Once the resealable pouch of the ELISA plate has been opened, care should be taken to close it tightly again including the desiccant.

4. Materials

4.1 Contents of the kit

BA D-0090	FOILS	Adhesive Foil – ready to use		
Content:	Adhesive foils in a rea	sealable pouch		
Number:	3 x 4 foils			
BA E-0030	WASH-CONC 50x	Wash Buffer Concentrate – concentrated 50x		
Content:	Buffer with a non-ionic detergent and physiological pH			
Volume:	3 x 20 ml/vial, purple	е сар		

BA E-0040	CONJUGATE Enzyme Conjugate – ready to use
Content:	Goat anti-rabbit immunoglobulins conjugated with peroxidase
Volume:	3 x 12 ml/vial, red cap
Description:	Species is goat
Hazard pictograms:	<u>!</u>
	GHS07
Signal word:	Warning
Hazardous ingredients:	2-methyl-2H-isothiazol-3-one
Hazard statements:	H317 May cause an allergic skin reaction.
Precautionary	P280 Wear protective gloves.
statements:	P302+P352 IF ON SKIN: Wash with plenty of water.
	P333+P313 If skin irritation or rash occurs: Get medical advice/attention.
	P501 Dispose of contents/container to an authorised waste collection point.
BA E-0055	SUBSTRATE Substrate – ready to use
Content:	Chromogenic substrate containing 3,3',5,5'-tetramethylbenzidine, substrate buffer and hydrogen peroxide
Volume:	3 x 12 ml/vial, black cap
BA E-0080	STOP-SOLN Stop Solution – ready to use
Content:	0.25 M sulfuric acid
Volume:	3 x 12 ml/vial, grey cap
BA E-0131	MADR MN Adrenaline Microtiter Strips – ready to use
Content:	$1 \ge 96$ wells ($12 \ge 8$) antigen precoated microwell plate in a resealable blue pouch with desiccant
BA E-0231	III NAD NMN Noradrenaline Microtiter Strips – ready to use
Content:	$1 ext{ x 96 wells (12x8) antigen precoated microwell plate in a resealable yellow pouch with desiccant$
BA E-0331	Dopamine Microtiter Strips – ready to use
Content:	$1 \ge 96$ wells ($12 \ge 8$) antigen precoated microwell plate in a resealable green pouch with desiccant
BA E-6110	ADR-AS Adrenaline Antiserum – ready to use
Content:	Rabbit anti-adrenaline antibody in buffer with proteins and non-mercury preservative, blue coloured
Volume:	1 x 6 ml/vial, blue cap
Description:	Species of antibody is rabbit, species of protein in buffer is bovine
BA E-6210	NAD-AS Noradrenaline Antiserum – ready to use
Content:	Rabbit anti-noradrenaline antibody in buffer with proteins and non-mercury preservative, yellow coloured
Volume:	1 x 6 ml/vial, yellow cap
Description:	Species of antibody is rabbit, species of protein in buffer is bovine
BA E-6310	DOP-AS Dopamine Antiserum – ready to use
Content:	Rabbit anti-dopamine antibody in buffer with proteins and non-mercury preservative, green coloured
Volume:	1 x 6 ml/vial, green cap
Description:	Species of antibody is rabbit, species of protein in buffer is bovine
BA E-6612	ACYL-REAG Acylation Reagent – ready to use
Content:	Acylation reagent in DMSO
Volume:	1 x 3 ml/vial, white cap

BA R-0050		
BA K-0050	ADJUST-BUFF	Adjustment Buffer – ready to use
Content:	TRIS buffer	
Volume:	2 x 4 ml/vial, green ca	ар
BA R-6611	ACYL-BUFF	Acylation Buffer – ready to use
Content:	Buffer with light alkali	ne pH for the acylation
Volume:	1 x 20 ml/vial, white c	сар
BA R-6613	ASSAY-BUFF	Assay Buffer – ready to use
Content:	1 M hydrochloric acid	and a non-mercury preservative
Volume:	1 x 6 ml/vial, grey cap)
Hazard pictograms:		
	GHS05	
Signal word:	Danger	
Hazard statements:	H314 Causes severe s	kin burns and eye damage.
Precautionary statements:	P303+P361+P353 IF (Rinse skin with water. P305+P351+P338 IF 1	IN EYES: Rinse cautiously with water for several minutes. Remove
	P310 Immediately call	ent and easy to do. Continue rinsing. I a doctor, a POISON CENTER. ents/container to an authorised waste collection point.
BA R-6614	P310 Immediately call P501 Dispose of conte	a doctor, a POISON CENTER. ents/container to an authorised waste collection point.
	P310 Immediately call P501 Dispose of conte COENZYME	l a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use
Content:	P310 Immediately call P501 Dispose of conte COENZYME S-adenosyl-L-methion	l a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use nine
Content: Volume:	P310 Immediately call P501 Dispose of conte COENZYME S-adenosyl-L-methion 1 x 4 ml/vial, purple c	l a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use nine cap
Content: Volume: BA R-6615	P310 Immediately call P501 Dispose of conte COENZYME S-adenosyl-L-methion 1 x 4 ml/vial, purple c ENZYME	l a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use nine cap Enzyme – lyophilized
Content: Volume: BA R-6615 Content:	P310 Immediately call P501 Dispose of conter COENZYME S-adenosyl-L-methion 1 x 4 ml/vial, purple c ENZYME Catechol-O-methyltrar	l a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use nine cap Enzyme – lyophilized
Content: Volume: BA R-6615 Content: Volume:	P310 Immediately call P501 Dispose of conter COENZYME S-adenosyl-L-methion 1 x 4 ml/vial, purple c ENZYME Catechol-O-methyltrar 6 vials, pink cap	l a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use nine cap Enzyme – lyophilized nsferase
Content: Volume: BA R-6615 Content: Volume: Description:	P310 Immediately call P501 Dispose of conter COENZYME S-adenosyl-L-methion 1 x 4 ml/vial, purple c ENZYME Catechol-O-methyltrar	I a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use line cap Enzyme – lyophilized hsferase
Content: Volume: BA R-6615 Content: Volume: Description: BA R-6617	P310 Immediately call P501 Dispose of conter COENZYME S-adenosyl-L-methion 1 x 4 ml/vial, purple c ENZYME Catechol-O-methyltrar 6 vials, pink cap Catechol-O-methyltrar	I a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use nine cap Enzyme – lyophilized nsferase msferase from pig liver Extraction Buffer – ready to use
Content: Volume: BA R-6615 Content: Volume: Description: BA R-6617 Content:	P310 Immediately call P501 Dispose of conter COENZYME S-adenosyl-L-methion 1 x 4 ml/vial, purple c ENZYME Catechol-O-methyltrar 6 vials, pink cap Catechol-O-methyltrar EXTRACT-BUFF Buffer containing carb	l a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use nine cap Enzyme – lyophilized nsferase nsferase from pig liver Extraction Buffer – ready to use
Content: Volume: BA R-6615 Content: Volume: Description: BA R-6617 Content: Volume:	P310 Immediately call P501 Dispose of conter COENZYME S-adenosyl-L-methion 1 x 4 ml/vial, purple c ENZYME Catechol-O-methyltrar 6 vials, pink cap Catechol-O-methyltrar EXTRACT-BUFF Buffer containing carb 1 x 6 ml/vial, brown c	I a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use nine cap Enzyme – lyophilized nsferase msferase from pig liver Extraction Buffer – ready to use conate cap
Content: Volume: BA R-6615 Content: Volume: Description: BA R-6617 Content: Volume: BA R-6618	P310 Immediately call P501 Dispose of conter COENZYME S-adenosyl-L-methion 1 x 4 ml/vial, purple c ENZYME Catechol-O-methyltrar 6 vials, pink cap Catechol-O-methyltrar EXTRACT-BUFF Buffer containing carb 1 x 6 ml/vial, brown c EXTRACT-PLATE 48	l a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use line cap Enzyme – lyophilized insferase insferase from pig liver Extraction Buffer – ready to use ionate cap Extraction Plate – ready to use
BA R-6614 Content: Volume: BA R-6615 Content: Volume: Description: BA R-6617 Content: Volume: BA R-6618 Content: BA R-6619	P310 Immediately call P501 Dispose of conter COENZYME S-adenosyl-L-methion 1 x 4 ml/vial, purple c ENZYME Catechol-O-methyltrar 6 vials, pink cap Catechol-O-methyltrar EXTRACT-BUFF Buffer containing carb 1 x 6 ml/vial, brown c EXTRACT-PLATE 48 2 x 48 well plates coar	I a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use nine tap Enzyme – lyophilized nsferase msferase from pig liver Extraction Buffer – ready to use toonate tap Extraction Plate – ready to use ted with boronate affinity gel in a resealable pouch
Content: Volume: BA R-6615 Content: Volume: Description: BA R-6617 Content: Volume: BA R-6618	P310 Immediately call P501 Dispose of conter COENZYME S-adenosyl-L-methion 1 x 4 ml/vial, purple c ENZYME Catechol-O-methyltrar 6 vials, pink cap Catechol-O-methyltrar EXTRACT-BUFF Buffer containing carb 1 x 6 ml/vial, brown c EXTRACT-PLATE 48	I a doctor, a POISON CENTER. ents/container to an authorised waste collection point. Coenzyme – ready to use ine cap Enzyme – lyophilized insferase insferase insferase from pig liver Extraction Buffer – ready to use ionate cap Extraction Plate – ready to use ted with boronate affinity gel in a resealable pouch Hydrochloric Acid – ready to use

4.2 Calibration and Controls

Standards and Controls – ready to use

Cat. no.	Component	Colour /Cap	Concer	tration [ng/ml]	Concen	tration [nmol/l]	Volume/ Vial
			ADR	NAD	DOP	ADR	NAD	DOP	
BA E-6601	STANDARD A	white	0	0	0	0	0	0	4 ml
BA E-6602	STANDARD B	yellow	1	5	10	5.5	30	65	4 ml
BA E-6603	STANDARD C	orange	4	20	40	22	118	261	4 ml
BA E-6604	STANDARD D	blue	15	75	150	82	443	980	4 ml
BA E-6605	STANDARD E	grey	50	250	500	273	1,478	3,265	4 ml
BA E-6606	STANDARD F	black	200	1,000	2,000	1,092	5,910	13,060	4 ml
BA E-6609	STANDARD A/B	purple	-	-	4.5	-	-	29	4 ml
BA E-6651	CONTROL 1	green	Refer to	QC-Repoi	rt for exp	ected valu	ie and ac	ceptable	4 ml
BA E-6652	CONTROL 2	red	range.						4 ml
Conversion:	adrenaline [ng/ml]	x 5.46 =	adrenaline	e [nmol/l]					
	noradrenaline [ng/	ml] x 5.91	= noradr	enaline [r	nmol/l]				
	dopamine [ng/ml]	x 6.53 = c	lopamine	[nmol/l]					

Content: Acidic buffer with non-mercury stabilizer, spiked with defined quantity of adrenaline, noradrenaline and dopamine

 Δ * for the determination of dopamine in plasma the additional **Standard A/B** is mandatory!

4.3 Additional materials required but not provided in the kit

- Water (deionized, distilled, or ultra-pure)
- Absorbent material (paper towel)

4.4 Additional equipment required but not provided in the kit

- Calibrated precision pipettes to dispense volumes between 10 700 μl; 1 ml
- Microtiter plate washing device (manual, semi-automated or automated)
- ELISA reader capable of reading absorbance at 450 nm and if possible 620 650 nm
- Microtiter plate shaker (shaking amplitude 3 mm; approx. 600 rpm)
- Vortex mixer

5. Sample collection, handling and storage

Plasma

Whole blood should be collected into centrifuge tubes containing EDTA as anti-coagulant and centrifuged according to manufacturer's instructions immediately after collection.

In case of hemolytic, icteric or lipemic samples see 2.2.1.

Storage: up to 6 hours at 2 – 8 °C, for longer period (up to 6 months) at -20 °C.

Repeated freezing and thawing should be avoided.

Urine

Spontaneous urine or 24-hour urine, collected in a bottle containing 10 – 15 ml of 6 M HCl, can be used.

If 24-hour urine is used please record the total volume of the collected urine.

Storage: up to 48 hours at 2 – 8 °C, up to 24 hours at room temperature, for longer periods (up to 6 months) at -20 °C. Repeated freezing and thawing should be avoided.

Avoid exposure to direct sunlight.

6. Test procedure

Allow all reagents and samples to reach room temperature and mix thoroughly by gentle inversion before use. Number the Extraction Plate and microwell plates (Microtiter Strips which are removed from the frame for usage should be marked accordingly to avoid any mix-up). Duplicate determinations are recommended.

The binding of the antisera and of the enzyme conjugate and the activity of the enzyme are temperature dependent. The higher the temperature, the higher the absorption values will be. Varying incubation times will have similar influences on the absorbance. The optimal temperature during the enzyme immunoassay is between 20 - 25 °C.

The use of a microtiter plate shaker with the following specifications is mandatory: shaking amplitude 3 mm; approx. 600 rpm. Shaking with differing settings might influence the results.

6.1 Preparation of reagents and further notes

Wash Buffer

Dilute the 20 ml Wash Buffer Concentrate **WASH-CONC 50X** with water to a final volume of 1000 ml. Storage: 2 months at 2 - 8 °C

Enzyme Solution

Reconstitute the content of the vial **ENZYME** with 1 ml water (deionized, distilled, or ultra-pure) and mix thoroughly. Add 0.3 ml of **COENZYME** followed by 0.7 ml of **ADJUST-BUFF**. The total volume of the Enzyme Solution is 2.0 ml.

The Enzyme Solution has to be prepared freshly prior to the assay (not longer than 10 – 15 minutes in advance). Discard after use!

Adrenaline Microtiter Strips, Noradrenaline Microtiter Strips and Dopamine Microtiter Strips

In rare cases residues of the blocking and stabilizing reagent can be seen in the wells as small, white dots or lines. These residues do not influence the quality of the product.

Acylation Reagent

The **ACYL-REAG** (BA E-6612) has a freezing point of 18.5 °C. To ensure that it is liquid when being used, it must be ensured that it has reached room temperature and forms a homogeneous, crystal-free solution before being used.

6.2 Sample preparation, extraction and acylation

 $\Delta +$ for the determination of dopamine in plasma the additional **Standard A/B** is mandatory!

- 1. Pipette 10 μl of standards, controls, urine samples and 300 μl of plasma samples into the respective wells of the EXTRACT-PLATE 48.
- 2. Add 250 µl of water (deionized, distilled, or ultra-pure) to the wells with standards, controls and urine samples.
- 3. Pipette 50 µl of ASSAY-BUFF into all wells.
- **4.** Pipette **50 μl** of **EXTRACT-BUFF** into all wells.
- 5. Cover plate with FOILS and incubate 30 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- **6.** Remove the foil. Empty plate and blot dry by tapping the inverted plate on absorbent material.
- 7. Pipette **1 ml** of **Wash Buffer** into all wells. Incubate the plate for **5 min** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm). Empty plate and blot dry by tapping the inverted plate on absorbent material.
- 8. Pipette another **1 ml** of **Wash Buffer** into all wells. Incubate the plate for **5 min** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm). Empty plate and blot dry by tapping the inverted plate on absorbent material.
- **9.** Pipette **150** µl of **ACYL-BUFF** into all wells.
- **10.** Pipette **25 μl** of **ACYL-REAG** into all wells.
- **11.** Incubate **15 min** at **RT** (20 25 °C) on a shaker (approx. 600 rpm).
- **12.** Empty plate and blot dry by tapping the inverted plate on absorbent material.
- **13.** Pipette **1 ml** of **Wash Buffer** into all wells. Incubate the plate for **10 min** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm). Empty plate and blot dry by tapping the inverted plate on absorbent material.
- **14.** Pipette **175** μl of **HCL** into all wells.
- **15.** Cover plate with **FOILS**. Incubate **10 min** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm). Remove the foil and discard.

/\ Do not decant the supernatant thereafter!

The following volumes of the supernatant are needed for the subsequent ELISA:

Adrenaline	100 µl	Noradrenaline	20 µl
Dopamine (standards + urine)	25 µl	Dopamine (plasma)	50 µl

5.3	Adrenaline ELISA
1.	Pipette 25 μ I of the Enzyme Solution (refer to 6.1) into all wells of the Adrenaline Microtiter Strips (III) (III)
2.	Pipette 100 μ I of the extracted standards, controls and samples into the appropriate wells.
3.	Incubate for 30 min at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
4.	Pipette 50 µl of the ADR-AS into all wells and cover plate with FOILS .
5.	Incubate for 2 h at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
6.	Remove the foil. Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 µl of Wash Buffer , discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
7.	Pipette 100 µl of the CONJUGATE into all wells.
8.	Incubate for 30 min at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
9.	Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 µl of Wash Buffer , discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
L O .	Pipette 100 μ I of the SUBSTRATE into all wells and incubate for 25 \pm 5 min at RT (20 – 25 °C) on a
	shaker (approx. 600 rpm). 🖄 Avoid exposure to direct sunlight!
.1.	Add 100 µl of the STOP-SOLN to all wells and shake the microtiter plate shortly.
L 2.	Read the absorbance of the solution in the wells within 10 minutes, using a microplate reader set to 450 nm (if available a reference wavelength between 620 nm and 650 nm is recommended).
.4 N	loradrenaline ELISA
1.	Pipette 25 μI of the Enzyme Solution (refer to 6.1) into all wells of the Noradrenaline Microtiter Strips III NAD NMN .
2.	Pipette 20 μ I of the extracted standards, controls and samples into the appropriate wells.
3.	Incubate for 30 min at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
4.	Pipette 50 μl of the NAD-AS into all wells and cover plate with FOILS .
5.	Incubate for 2 h at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
6.	Remove the foil. Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 µI of Wash Buffer , discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
7.	Pipette 100 µl of the CONJUGATE into all wells.
8.	Incubate for 30 min at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
9.	Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 µI of Wash Buffer , discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
L O .	Pipette 100 µl of the SUBSTRATE into all wells and incubate for 25 ± 5 min at RT (20 - 25 °C) on a
	shaker (approx. 600 rpm). 🖄 Avoid exposure to direct sunlight!
L 1 .	Add 100 µl of the STOP-SOLN to all wells and shake the microtiter plate shortly.
12.	

6.5 Dopamine ELISA

1.	Pipette 25 μ I of the Enzyme Solution (refer to 6.1) into all wells of the Dopamine Microtiter Strips \square DOP .
2.	Pipette 25 μ I of the extracted standards , controls , urine samples and 50 μ I of the extracted plasma samples into the appropriate wells.
3.	Add 25 µl of HCL to the standards, controls and urine samples.
4.	Incubate for 30 min at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
5.	Pipette 50 µl of the NAD-AS into all wells and cover plate with FOILS .
6.	Incubate for 2 h at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
7.	Remove the foil. Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 µl of Wash Buffer , discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
8.	Pipette 100 μl of the CONJUGATE into all wells.
9.	Incubate for 30 min at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
10.	Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 µ I of Wash Buffer , discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
11.	Pipette 100 µl of the SUBSTRATE into all wells and incubate for 25 ± 5 min at RT (20 – 25 °C)
	on a shaker (approx. 600 rpm). Avoid exposure to direct sunlight!
12.	Add 100 µl of the STOP-SOLN to all wells and shake the microtiter plate shortly.
13.	Read the absorbance of the solution in the wells within 10 minutes, using a microplate reader set to 450 nm (if available a reference wavelength between 620 nm and 650 nm is recommended).
7.	Calculation of results

		Adrenaline	Noradrenaline	Dopamine
Measuring range	Urine	0.7 – 200 ng/ml	2.5 – 1,000 ng/ml	4.8 – 2,000 ng/ml
	Plasma	18 – 6,667 pg/ml	93 – 33,333 pg/ml	75 – 33,333 pg/ml

The standard curve, which can be used to determine the concentration of the unknown samples, is obtained by plotting the absorbance readings (calculate the mean absorbance) of the standards (linear, y-axis) against the corresponding standard concentrations (logarithmic, x-axis) using a concentration of 0.001 ng/ml for Standard A (this alignment is mandatory because of the logarithmic presentation of the data). Use non-linear regression for curve fitting (e.g. 4-parameter, marquardt).

This assay is a competitive assay. This means: the OD-values are decreasing with increasing concentrations of the analyte. OD-values found below the standard curve correspond to high concentrations of the analyte in the sample and have to be reported as being positive.

Urine samples and controls

The concentrations of the **urine samples** and the **Controls** can be read directly from the standard curve. Calculate the 24 h excretion for each urine sample: $\mu g/24h = \mu g/l \times l/24h$

Plasma samples

The read **Adrenaline and Noradrenaline** concentrations of the **plasma samples** have to be **divided by 30**. The read **Dopamine** concentrations of the **plasma samples** have to be **divided by 60**.

Conversion:


Adrenaline [ng/ml] x 5.46 = Adrenaline [nmol/l] Noradrenaline [ng/ml] x 5.91 = Noradrenaline [nmol/l] Dopamine [ng/ml] x 6.53 = Dopamine [nmol/l]


7.1 Expected reference value

It is strongly recommended that each laboratory should determine its own reference values.

	Adrenaline	Noradrenaline	Dopamine
24-hour urine	< 20 µg/day	< 90 µg/day	< 600 µg/day
	(110 nmol/day)	(535 nmol/day)	(3.900 nmol/day)
Plasma	< 100 pg/ml	< 600 pg/ml	< 100 pg/ml

7.2 Typical standard curve





8. Control samples

It is recommended to use control samples according to national regulations. Use controls at both normal and pathological levels. Commercially obtained control samples should be treated like unknown samples. Control samples should fall within established confidence limits. The confidence limits of the kit controls are indicated on the QC-Report.

9. Assay characteristics

9.1 Performance data

Analytical Sensitivity							
		Adrenaline	Noradrenaline	Dopamine			
Limit of Plank (LOP)	Urine [ng/ml]	0.8	1.5	2.2			
Limit of Blank (LOB)	Plasma [pg/ml]	9.3	32	43			
Limit of Datastian (LOD)	Urine [ng/ml]	0.9	1.7	2.5			
Limit of Detection (LOD)	Plasma [pg/ml]	10	36	49			
Limit of Quantification (LOQ)	Urine [ng/ml]	0.7	2.5	4.8			
Limit of Quantification (LOQ)	Plasma [pg/ml]	18	93	75			

Substance	Cross Reactivity [%]				
Substance	Adrenaline	Noradrenaline	Dopamine		
Derivatized Adrenaline	100	0.08	0.02		
Derivatized Noradrenaline	0.13	100	6.4		
Derivatized Dopamine	< 0.01	0.03	100		
Metanephrine	0.18	< 0.01	< 0.01		
Normetanephrine	< 0.01	0.16	0.01		
3-Methoxytyramine	< 0.01	< 0.01	0.49		
3-Methoxy-4-hydroxyphenylglycol	< 0.01	< 0.01	< 0.01		
Tyramine	< 0.01	< 0.01	0.18		
Phenylalanine, Caffeinic acid, L-Dopa, Homovanillic acid, Tyrosine, 3-Methoxy-4-hydroxymandelic acid	< 0.01	< 0.01	< 0.01		

Precision							
Intra-Assay Uri	ne (n = 60)			Intra-Assay Plas	ma (n = 60))	
	Sample	Range [ng/ml]	CV [%]		Sample	Range [pg/ml]	CV [%]
Adrenaline	1	6.2 ± 1.1	17.4	Adrenaline	1	64.7 ± 15.9	24.7
	2	21.4 ± 2.7	12.4		2	258 ± 32.5	12.7
	3	59.4 ± 7.8	13.1		3	948 ± 105	11.0
Noradrenaline	1	26.1 ± 3.6	13.8	Noradrenaline	1	510 ± 65	12.8
	2	97 ± 12.8	13.4		2	1,358 ± 194	14.3
	3	267 ± 35	13.1		3	3,363 ± 374	11.1
Dopamine	1	82 ± 16.1	19.7	Dopamine	1	75 ± 22	29.8
	2	253 ± 41.1	16.3		2	353 ± 86	24.4
	3	714 ± 67	9.4		3	1,187 ± 293	24.9
Inter-Assay Uri	ne (n = 33)			Inter-Assay Plasma (n = 18)			
	Sample	Range [ng/ml]	CV [%]		Sample	Range [pg/ml]	CV [%]
Adrenaline	1	5.2 ± 0.9	17.9	Adrenaline	1	76.4 ± 11.1	14.5
	2	17.8 ± 2.1	11.7		2	247 ± 27.5	11.1
	3	54.2 ± 6.6	12.1		3	771 ± 101	13.1
Noradrenaline	1	19.5 ± 3.9	20.0	Noradrenaline	1	445 ± 40.9	9.2
	2	80.6 ± 10.6	13.2		2	1,232 ± 134	10.9
	3	226 ± 39.5	17.4		3	3,283 ± 302	9.2
Dopamine	1	79.3 ± 18.8	23.7	Dopamine	1	238 ± 67.0	28.2
	2	222 ± 27.0	12.1		2	1,072 ± 201	18.8
-	3	630 ± 69.0	11.0]	3	3,449 ± 491	14.2

LOI-IO-LOI				
		Sample	Mean \pm SD [ng/ml]	CV [%]
	Urine	1	6.6 ± 0.9	13.7
Adrenaline (n = 5)		2	23.5 ± 1.5	6.2
	Diagma	Sample	Mean ± SD [pg/ml]	CV [%]
	Plasma	1	202 ± 26.7	11.8
Noradrenaline (n = 6)		Sample	Mean ± SD [ng/ml]	CV [%]
	Urine	1	124 ± 13.2	10.7
		2	29.3 ± 3.7	12.6
	Diagona	Sample	Mean ± SD [pg/ml]	CV [%]
	Plasma	1	1,071 ± 97.3	5.3
Dopamine (n = 6)		Sample	Mean ± SD [ng/ml]	CV [%]
	Urine	1	189 ± 14.7	7.8
		2	678 ± 39.3	5.8

Recovery						
	Urine	Range [ng/ml]	Mean [%]	Range [%]		
Adrenaline	Unne	0.27 - 61	95	89 - 98		
Aurenaline	Diserse	Range [pg/ml]	Mean [%]	Range [%]		
	Plasma	9.1 - 4,268	105	88 - 117		
Newsday	Urine	Range [ng/ml]	Mean [%]	Range [%]		
	Unne	1.8 - 249	96	70 - 118		
Noradrenaline	Plasma	Range [pg/ml]	Mean [%]	Range [%]		
		51 - 14,251	87	75 – 107		
Deservise	Urine	Range [ng/ml]	Mean [%]	Range [%]		
	Unne	9.2 - 762	112	106 - 117		
Dopamine	Plasma	Range [pg/ml]	Mean [%]	Range [%]		
	FIASIIIA	57.4 - 16,054	89	84 - 92		

Linearity						
		Serial dilution up to	Mean [%]	Range [%]		
Adronalina	Urine	1:512	108	92 - 123		
Adrenaline	Plasma	1:512	105	94 - 115		
Nie werde eine eitere	Urine	1:512	112	100 - 127		
Noradrenaline	Plasma	1:512	112	102 - 125		
Demonstra	Urine	1:512	104	83 - 126		
Dopamine	Plasma	1:512	106	85 - 132		

9.2 Metrological Traceability

The values assigned to the standards and controls of the 3-CAT ELISA Fast Track are traceable to SI Units by weighing with quality-controlled analyte.

Standards and Controls				
	Uncertainty [%]			
Adrenaline	3.5			
Noradrenaline	4.1			
Dopamine	2.5			

3-CAT ELISA Fast	Track			
		Concentration [ng/ml]	Expanded Uncertainty [%] k = 2^*	
	Urino	5.2	36.5	
Adrenaline	Urine –	17.8	24.4	
Aurenaline		54.2	25.2	
	Diseme	Concentration [pg/ml]	Expanded Uncertainty [%] k = 2^*	
	Plasma –	76.4	29.8	
		Concentration [ng/ml]	Expanded Uncertainty [%] k = 2^*	
	Urine -	19.5	40.8	
Noradropalina		80.6	27.6	
Noradrenaline		226	35.7	
		Concentration [pg/ml]	Expanded Uncertainty [%] k = 2^*	
	Plasma –	445	20.1	
		Concentration [ng/ml]	Expanded Uncertainty [%] k = 2^*	
Dopamine	Urine	79.3	47.7	
		222	24.7	
		630	22.6	
	Diseme	Concentration [pg/ml]	Expanded Uncertainty [%] k = 2^*	
	Plasma –	238	56.6	

* This defines an interval about the measured result that will include the true value with a probability of 95%.

10. References/Literature

- 1. Kim, H., et al., Vitamin C prevents stress-induced damage on the heart caused by the death of cardiomyocytes, through down-regulation of the excessive production of catecholamine, TNF-a, and ROS production in Gulo(-/-)Vit C-Insufficient mice. Free Radic Biol Med, 2013. **65**: p. 573-583.
- 2. Bada, A.A., et al., *Peripheral vasodilatation determines cardiac output in exercising humans: insight from atrial pacing.* J Physiol, 2012. **590**(8): p. 2051-60.
- 3. Parks, C.G., et al., *Employment and work schedule are related to telomere length in women.* Occup Environ Med, 2011. **68**(8): p. 582-9.
- 4. Eisenhofer, G., C. Pamporaki, and J.W.M. Lenders, *Biochemical Assessment of Pheochromocytoma and Paraganglioma.* Endocr Rev, 2023. **44**(5): p. 862-909.

For updated literature or any other information please contact your local supplier.

11. Changes

Version	Release Date	Chapter	Change
19.0	2023-11-28	4.1	- Hazard labelling updated according to SDS
20.0	2025-05-20	2.1 2.2.2 4.1 9.1 9.2 10	 Updated Drugs + foods that affect concentrations of catecholamines added BA E-0040: Hazard labelling updated according to SDS Lot-to-lot added; recovery urine updated Metrological Traceability added Updated

Symbols:

+2 °C	Storage temperature	** *	Manufacturer	Σ	Contains sufficient for <n> tests</n>
$\mathbf{\Sigma}$	Use-by date	LOT	Batch code	IVD	For in-vitro diagnostic use only!
Ĩ	Consult instructions for use	CONT	Content	CE	CE marking of conformity
	Caution	REF	Catalogue number		Distributor
<u>~</u>	Date of manufacture	\otimes	Do not re-use		